reports
Aura Biosciences Announces Pricing of Public Offering of Common Stock ...
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,43...
Aura Biosciences Announces Proposed Public Offering of Common Stock an...
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common sto...
Aura Biosciences Reports First Quarter 2025 Financial Results and Busi...
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter e...
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025.Fireside Chat...
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of D...
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She...
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial R...
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-stage biotechnology company dev...
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscl...
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC Aura Hosting with Key O...
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial ...
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precisi...
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025.Fireside Chat at 9:10 a.m. ET.Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Fireside Chat at 8:00 a.m. ...
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthC...
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET. The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & ...
Aura Biosciences Reports Third Quarter 2024 Financial Results and Busi...
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC); Phase 1 Expansion Preparation in Progress Strong Cash Position Expected to Support Operations into 2H 2026 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TDS TELEPHONE AND DATA SYSTEMS INC.
JBLU JETBLUE AIRWAYS CORPORATION
MDU MDU RESOURCES GROUP INC
CMA COMERICA INCORPORATED
USM UNITED STATES CELLULAR CORP
VALU VALUE LINE INC.
CIA CITIZENS INC. CL A
AIRG AIRGAIN
LW LAMB WESTON HOLDINGS INC.
ROKU ROKU INC. CLASS A
RDVT RED VIOLET
EAT AMREST HOLDINGS SE
NEON NEONODE INC.
PTON PELOTON INTERACTIVE INC. CLASS A
CRMD CORMEDIX INC.
PLRX PLIANT THERAPEUTICS
RNA AVIDITY BIOSCIENCES
ALKT ALKAMI TECHNOLOGY INC
ULCC FRONTIER GROUP HLDGS INC
RELY REMITLY GLOBAL INC
SNCY SUN COUNTRY AIRLINES HLDGS INC
NN NEXTNAV INC
OPFI OPPFI INC
AURA AURA BIOSCIENCES INC
TYRA TYRA BIOSCIENCES INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
SLG SL GREEN REALTY CORP.
WGS GENEDX HOLDINGS CORP.
LXEO LEXEO THERAPEUTICS INC
GDLC GRAYSCALE DIGITAL LARGE CAP FD COM
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
RDDT REDDIT INC
Multiple Clinical Complete Responses Demonstrated Following Single Low...
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Aura Hosting with Key Opinion Leaders at 4.30 pm ET Today BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: AU...
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluat...
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-01...
Aura Biosciences to Host a Urologic Oncology Investor Event to Present...
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that it will host a virtual urologic oncology investor e...
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Members of Aura’s senior management team will participate in one-on-one investor meetings.H.C. Wainwright 26th Annual...
Aura Biosciences Announces the Presentation of Phase 2 End of Study Da...
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that Ph...
Aura Biosciences Reports Second Quarter 2024 Financial Results and Bus...
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-stage Choroidal Melanoma to be Presented at Retina Society Annual Meeting Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-st...
Aura Biosciences to Participate in the Jefferies Global Healthcare Con...
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET. The live webcast of the presentation will be available on the “Investors & Media” page under the “...
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard ...
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, . The event will feature Carol Shields, MD (Wills Eye Hospital), Hakan Demirci, MD (University of Michigan), and Mandeep Sagoo, MB, P...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.